Tyra’s dabogratinib advances toward pivotal oncology trials
Dabogratinib, a highly selective oral FGFR3 inhibitor, is advancing toward pivotal trials in IR NMIBC, LG UTUC and ACH, supported by strong Phase 2 efficacy and safety data.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.